Attached files

file filename
8-K - 8-K - KINETIC CONCEPTS INCr2qtr20118k072611.htm
Exhibit 99.1
 
KCI Logo
 
 

FOR MORE INFORMATION, CONTACT:
 
Investors:
Todd Wyatt
Office:  210-255-6157
Wireless:  210-347-3540
todd.wyatt@kci1.com
Media:
Kevin Belgrade
Office:  210-255-6232
Wireless:  210-216-1236
kevin.belgrade@kci1.com
 



KINETIC CONCEPTS REPORTS SECOND QUARTER
AND FIRST HALF 2011 FINANCIAL RESULTS


Second Quarter Highlights

 
-  Worldwide revenue of $519.8 million, up 4% from the prior-year period, as reported, and up 1% on a constant currency basis

 
-  Worldwide Active Healing Solutions™ (“AHS”) revenue of $358.0 million, up 3% from $347.7 million in the prior-year period, as reported, and comparable to the prior-year period on a constant currency basis

 
-  Worldwide LifeCell™ revenue of $96.3 million, up 15% from the prior-year period on both a reported and constant currency basis

 
-  Worldwide Therapeutic Support Systems (“TSS”) revenue of $65.5 million, down 1% from $66.3 million in the prior-year period, as reported, and down 6% on a constant currency basis

 
-  Net earnings per diluted share of $1.09, up 45% from the prior-year period, as reported, and up 22% on an adjusted non-GAAP basis



San Antonio, Texas, July 26, 2011 – Kinetic Concepts, Inc. (NYSE: KCI) today reported second quarter 2011 total revenue of $519.8 million, an increase of 4% from the second quarter of 2010.  Total revenue for the first half of 2011 was $1.02 billion, which also represented a 4% increase from the prior-year period.  Foreign currency exchange movements favorably impacted total revenue by 3% for the second quarter of 2011 and 2% for the first half of 2011 compared to the corresponding periods of the prior year.

Net earnings for the second quarter of 2011 were $81.4 million, an increase of 52% compared to $53.6 million for the same period one year ago.  Net earnings per diluted share for the second quarter of 2011 were $1.09 compared to $0.75, or an increase of 45%, from the same period in the prior year.  On a non-GAAP basis, excluding the effects of certain acquisition-related costs and charges recorded in the second quarter of 2010 associated with our TSS portfolio rationalization and Global Business Transformation, net earnings per diluted share were $1.23 for the second quarter of 2011 compared to $1.01 from the same period of the prior year.  Fully diluted, weighted average shares outstanding were 74.9 million for the second quarter of 2011 and 73.4 million for the first six months of 2011, representing increases of 4% and 2%, respectively, from the corresponding periods of the prior year.
 
“Despite a challenging operating environment, KCI delivered solid financial performance including stable revenue, and strong earnings and cash flow growth year over year,” said Catherine Burzik, President and Chief Executive Officer of KCI.  “After the quarter, we announced an agreement to be acquired for $6.3 billion by a consortium of well-respected private equity investors whose interest in KCI represents an endorsement of our market leadership, differentiated products and services and consistently strong performance.  We’re proud of what we’ve achieved in the marketplace and will continue making the right investments in people, product innovation and commercial capabilities that help the medical community deliver superior outcomes to patients.”
 
 
 

 

Revenue Recap – Second Quarter and First Half of 2011

Worldwide revenue from AHS products was $358.0 million for the second quarter of 2011 and $698.5 million for the first half of 2011 compared to $347.7 million and $680.7 million, respectively, for the corresponding periods of 2010.  The growth in second quarter worldwide AHS revenue was attributable primarily to favorable foreign currency movements and higher volumes from new markets and recent product introductions, partially offset by lower rental revenue in established markets.  Foreign currency exchange movements favorably impacted worldwide AHS revenues in the second quarter and first half of 2011 by 3% and 2%, respectively, compared to the prior-year periods.

AHS revenue from the Americas region of $266.9 million for the second quarter of 2011 was comparable to the prior-year period and increased 3% from the first quarter of 2011.  AHS Americas revenue for the first half of 2011 was $524.7 million, a 2% increase from the prior-year period resulting from a combination of increased V.A.C.® disposable sales and the adoption of new negative pressure-based therapies we have introduced in the U.S., partially offset by an expected decrease in realized rental pricing.  Foreign currency exchange movements did not have a significant impact on AHS Americas revenue as compared to the prior-year periods.

AHS EMEA revenue was $75.2 million and $144.1 million, respectively, for the second quarter and first half of 2011 compared to $71.9 million and $147.5 million, respectively, for the corresponding periods of the prior year.  Foreign currency exchange rate movements favorably impacted second quarter and first half 2011 AHS EMEA revenue by 12% and 6%, respectively, compared to the prior-year periods.  On a constant currency basis, AHS EMEA revenue decreased 8% during both the second quarter and the first half of 2011 compared to the prior-year periods due to increased European Union healthcare spending austerity measures combined with continued pricing pressures, partially offset by volume growth for V.A.C.Via™.

AHS APAC revenue was $16.0 million and $29.7 million, respectively, for the second quarter and first half of 2011 compared to $9.1 million and $16.6 million, respectively, in the prior-year periods.  Foreign currency exchange rate movements favorably impacted second quarter and first half 2011 AHS APAC revenue by 21% and 18%, respectively, compared to the prior-year periods.  On a constant currency basis, AHS APAC revenue increased 54% and 61%, respectively, during the second quarter and the first half of 2011 compared to the prior-year periods due primarily to higher unit volumes, particularly in Japan, and improved average pricing resulting from favorable product mix by country.

Worldwide LifeCell revenue was $96.3 million and $189.3 million, respectively, for the second quarter and first half of 2011, up 15% and 16%, respectively, from the corresponding prior-year periods.  LifeCell EMEA sales totaled $3.1 million and $5.8 million, respectively, for the second quarter and first half of 2011, up from $1.6 million and $2.6 million, respectively, during the prior-year periods, with growth reported in all geographic locations where we have launched our LifeCell products.  Foreign currency exchange movements did not have a significant impact on worldwide LifeCell revenue as compared to the second quarter and first half of the prior year.

Worldwide TSS revenue was $65.5 million for the second quarter and $133.2 million for the first half of 2011 compared to $66.3 million and $140.1 million, respectively, for the same periods one year ago.  Second quarter 2011 TSS revenue declined 6% on a constant currency basis compared to the same period one year ago due primarily to lower rental volumes in both wound care and bariatric care as hospitals shifted towards capital purchases and away from rentals.  TSS Americas revenue was $41.0 million for the second quarter and $85.5 million for the first half of 2011 compared to $44.6 million and $93.0 million, respectively, for the same periods in the prior year.  TSS EMEA revenue was $24.2 million for the second quarter and $47.1 million for the first half of 2011 compared to $21.6 million and $46.5 million, respectively, for the same periods in the prior year.  Foreign currency exchange rate movements favorably impacted Americas and EMEA TSS revenue by 1% and 13%, respectively, in the second quarter of 2011 and 1% and 6%, respectively, in the first half of 2011 compared to the same periods of the prior year.
 
 
 

 

Profit Margins

Gross profit for the second quarter and first six months of 2011 was $313.1 million and $602.0 million, respectively, representing increases of 12% and 9%, respectively, from the same periods of the prior year.  Gross profit margin was 60% for the second quarter of 2011, an increase of approximately 400 basis points from the same period one year ago.  The gross profit margin increase was due primarily to lower royalty expense associated with our previous license agreement with Wake Forest University, higher gross margins associated with our LifeCell business unit and lower rental fleet depreciation, partially offset by the additional investment in our AHS sales force during the second half of 2010 and first half of 2011.  During the second quarter of 2010, the Company recorded $23.0 million in royalty expense associated with our previously-existing licensing agreement with Wake Forest.

Selling, general and administrative (“SG&A”) expenses for the second quarter and first six months of 2011 were $152.2 million and $296.5 million, respectively, representing increases of 3% and 5%, respectively, from the same periods of the prior year.  SG&A increases included the impact of unfavorable foreign currency movements, selling costs associated with our LifeCell division, higher costs associated with geographic expansion and new product launches and acquisition-related costs, partially offset by reduced litigation costs and prior-year charges associated with our TSS portfolio rationalization and our Global Business Transformation.

Research and development expenses for the second quarter and first six months of 2011 were $23.4 million and $44.6 million, respectively, representing an increase of 8% from the second quarter of 2010 and a decrease of 4% from the first half of 2010.  Research and development expenses for the first half of 2011 were lower than the prior-year period due primarily to higher costs in the first quarter of 2010 as we prepared for new product launches including V.A.C.Via and Prevena.  Research and development expenses were higher during the second quarter of 2011 compared to the prior-year period due to increased headcount following the formation of our Center for Advanced Research and Technology (“ART”).  The goal of ART is to identify, develop and acquire new technologies to support product development in our AHS, LifeCell and TSS businesses to broaden our existing portfolio with future advanced technologies.  During the second quarter of 2011, total research and development expenses represented 4.5% of revenue compared to 4.4% for the same period one year ago.

Operating earnings for the second quarter and first six months of 2011 were $128.6 million and $243.2 million, respectively, representing increases of 27% and 20%, respectively, from the corresponding periods of the prior year.  The increase in operating earnings resulted from a combination of lower royalty expense, favorable product mix and prior-year charges associated with our TSS portfolio rationalization and Global Business Transformation.  During the second quarter of 2011, the Company recorded $1.2 million in expenses associated with the recently-announced leveraged buyout transaction.


Other Income/Expense

Second quarter 2011 interest expense decreased to $17.2 million compared to $22.3 million in the same period of the prior year due to scheduled and voluntary debt payments made over the last twelve months, as well as lower interest rates due, in part, to our debt refinancing completed in the first quarter of the year.  Long-term debt outstanding, on a debt-instrument basis, as of June 30, 2011 consisted of a senior secured term loan of $536.3 million due 2016 and $690.0 million of 3.25% senior convertible notes due 2015.  Foreign currency transaction losses decreased to $206,000 in the second quarter of 2011 compared to $2.7 million in the prior-year period due primarily to reduced foreign currency exposures.
 
 
 

 
 
Income Tax Rate

The effective income tax rate for the second quarter and first six months of 2011 was 27.0% and 27.1%, respectively, compared to 30.0% for both corresponding periods in 2010.  The decrease in the effective income tax rate for the second quarter and first six months of 2011 was due primarily to a higher percentage of taxable income being generated in lower-tax foreign jurisdictions.


Financial Position

Total cash at quarter-end was $498.4 million, an increase of $181.8 million from year-end 2010.  Operating cash flow less net capital expenditures for the first half of 2011 was $162.5 million compared to $99.0 million in the prior-year period due primarily to higher net earnings and lower cash outlays for royalty payments, inventory purchases, interest and income taxes, partially offset by lower cash collections and higher capital expenditures.  Total long-term debt outstanding at June 30, 2011 was $1.125 billion on a GAAP-basis and $1.226 billion on an economic, or debt-instrument, basis.


Subsequent Event

On July 12, 2011, KCI entered into a definitive merger agreement under which a consortium of funds advised by Apax Partners, together with controlled affiliates of Canada Pension Plan Investment Board and Canada’s Public Sector Pension Investment Board, will acquire KCI for $68.50 per share in cash in a transaction valued at $6.3 billion, inclusive of KCI’s outstanding debt.  The merger agreement also provides for a 40-day “go shop” period, during which KCI is permitted to encourage and solicit alternative proposals from third parties.


Outlook

The Company reaffirmed its 2011 financial guidance, based on current information and expectations as of July 26, 2011 (in millions, except per share data) as follows:

         
% Change
 
FY 2010
 
FY 2011
 
from 2010
Total revenue
$ 2,018   $ 2,050 – $ 2,090   2% – 4%
           
Diluted EPS – GAAP basis
$ 3.57   $ 4.35 – $ 4.45   22% – 25%
Acquisition-related adjustments:
         
   Amortization-related adjustments
0.43   0.35    
   Non-cash interest – accounting
         
      for convertible debt
0.18   0.19    
Restructuring and other charges
0.11   0.07 – 0.09    
           
Adjusted Diluted EPS – non-GAAP basis
$ 4.29   $ 4.96 – $ 5.08   16% – 18%
           
Diluted weighted average shares outstanding
71.7   73.5 – 74.5   3% – 4%
 
 
 

 
 
Non-GAAP Financial Information

Within this document, we have included our results for the second quarter and six months ended June 30, 2011 along with our outlook on a non-GAAP basis to exclude the impact of specified non-cash expenses associated with our 2008 acquisition of LifeCell and the impact of other charges, including costs associated with our TSS portfolio rationalization and our Global Business Transformation incurred in the second quarter of 2010, debt refinancing costs incurred during the first quarter of 2011 and acquisition-related costs incurred during the second quarter of 2011.  In addition, we have presented supplemental revenue data on a non-GAAP basis to exclude the impact of foreign currency fluctuations between 2010 and 2011.  These non-GAAP financial measures do not replace the presentation of our GAAP results and outlook.  We have provided this supplemental non-GAAP information because it may provide meaningful information regarding our results and outlook on a basis that better facilitates an understanding of our expected results of operations which may not be otherwise apparent under GAAP.  Management uses this non-GAAP financial information, along with GAAP information, for reviewing the operating results of its business segments and for analyzing potential future business trends.  In addition, we believe some investors may use this information in a similar fashion.  A reconciliation of our GAAP selected financial information for the periods presented to the non-GAAP selected financial information provided is included herein.


Earnings Release Conference Call

As previously announced, we have scheduled an earnings release conference call for 8:30 a.m. Eastern Daylight Time today, Tuesday, July 26, 2011.  The dial-in numbers for this conference call are as follows:

Domestic Dial-in Number:
 
     877-537-8066
International Dial-in Number:
 
     +706-758-3983
Conference ID Number:
 
     83431776

This call is being webcast and can be accessed at the Kinetic Concepts, Inc. Web site at http://www.kci1.com/investor/index.asp, by clicking on Webcast – Q2 2011 Kinetic Concepts, Inc. Earnings Conference Call.  An archive of the web cast will be available until July 25, 2012 at http://www.kci1.com/investor/index.asp.

KCI's business outlook as of today is expected to be available on KCI's Investor Relations web site.  KCI does not currently expect to update this business outlook until the release of KCI's next quarterly earnings announcement, notwithstanding subsequent developments.  Although KCI undertakes no duty to update its business outlook, KCI may update the full business outlook or any portion thereof at any time.


About KCI

Kinetic Concepts, Inc. (NYSE:KCI), is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets.  Headquartered in San Antonio, Texas, KCI's success spans more than three decades and can be traced to a history deeply rooted in innovation and a passion for significantly improving the healing and the lives of patients around the world.

The Company employs approximately 7,000 people and markets its products in more than 20 countries.  For more information about KCI and how its products are changing the practice of medicine, visit www.KCI1.com.
 
 
 

 
 
Additional Information about the Merger and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed acquisition of Kinetic Concepts, Inc. (“KCI”) by a consortium comprised of funds advised by Apax Partners, L.P. and Apax Partners LLP, together with controlled affiliates of Canada Pension Plan Investment Board and Canada’s Public Sector Pension Investment Board. KCI plans to file a proxy statement with the SEC. INVESTORS AND SECURITY HOLDERS OF KCI ARE ADVISED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION.  The definitive proxy statement will be mailed to shareholders of KCI.  Investors and security holders may obtain a free copy of the proxy statement when it becomes available, and other documents filed by KCI with the SEC, at the SEC’s web site at http://www.sec.gov.  Free copies of the proxy statement, when it becomes available, and KCI’s other filings with the SEC may also be obtained from KCI by directing a request to Kinetic Concepts, Inc., Attention: Investor Relations, 8023 Vantage Drive, San Antonio, TX 78230-4726, or by calling 210-255-6157.


Participants in Solicitation

KCI and its directors, executive officers and other members of its management and employees may be deemed to be soliciting proxies from KCI’s shareholders in favor of the proposed acquisition.  Information regarding KCI’s directors and executive officers is available in its 2010 Annual Report on Form 10-K filed with the SEC on March 1, 2011, and definitive proxy statement relating to its 2011 Annual Meeting of Shareholders filed with the SEC on April 15, 2011.  Shareholders may obtain additional information regarding the interests of KCI and its directors and executive officers in the proposed acquisition, which may be different than those of KCI’s shareholders generally, by reading the proxy statement and other relevant documents filed with the SEC when they become available.


Forward-Looking Statements

This press release contains forward-looking statements including, among other things, management's outlook, estimates of future performance, revenue, earnings per share, growth objectives and weighted average shares outstanding.  The forward-looking statements contained herein are based on our current expectations and are subject to a number of risks and uncertainties that could cause us to fail to achieve our current financial projections and other expectations, such as changes in the demand for V.A.C. Therapy resulting from increased competition, the seasonal slowing of V.A.C. Therapy unit growth in the fourth and first quarter of each year, changes in payer reimbursement policies or in our ability to protect our intellectual property rights, or the possibility that the announced merger with Apax Partners and controlled affiliates of Canada Pension Plan Investment Board and Canada’s Public Sector Pension Investment Board is not consummated.  All information set forth in this release and its attachments is as of July 26, 2011.  We undertake no duty to update this information.  More information about potential factors that could cause our results to differ or adversely affect our business and financial results is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in our quarterly report on Form 10-Q for the quarterly period ended March 31, 2011, including, among other sections, under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations."  These reports are on file with the SEC and available at the SEC's website at www.sec.gov.  Additional information may also be set forth in those sections in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011, which is expected to be filed with the SEC in early August 2011.
 
 
 

 
 
KINETIC CONCEPTS, INC. AND SUBSIDIARIES
 
Condensed Consolidated Statements of Earnings
 
(in thousands, except per share data)
 
(unaudited)
 
   
   
 
Three months ended June 30,
   
Six months ended June 30,
 
             
%
               
%
 
 
2011
   
2010
   
Change
   
2011
   
2010
   
Change
 
Revenue:
                                 
   Rental
$ 279,314     $ 283,084     (1.3 )%     $ 558,014     $ 563,075     (0.9 )%  
   Sales
  240,516       214,688     12.0       463,000       420,502     10.1  
                                           
Total revenue
  519,830       497,772     4.4       1,021,014       983,577     3.8  
                                           
Rental expenses
  146,353       155,622     (6.0 )           296,845       308,841     (3.9 )      
Cost of sales
  60,418       62,307     (3.0 )           122,137       123,231     (0.9 )      
                                           
Gross profit
  313,059       279,843     11.9       602,032       551,505     9.2  
                                           
Selling, general and administrative expenses
  152,155       147,212     3.4       296,522       282,591     4.9  
Research and development expenses
  23,411       21,718     7.8       44,594       46,502     (4.1 )      
Acquired intangible asset amortization
  8,856       9,556     (7.3 )           17,712       19,715     (10.2 )      
                                           
Operating earnings
  128,637       101,357     26.9       243,204       202,697     20.0  
                                           
Interest income and other
  267       143     86.7       469       279     68.1  
Interest expense
  (17,157 )     (22,264 )   (22.9 )           (37,997 )     (45,826 )   (17.1 )      
Foreign currency loss
  (206 )     (2,657 )   (92.2 )           (25 )     (5,267 )   (99.5 )      
                                           
Earnings before income taxes
  111,541       76,579     45.7       205,651       151,883     35.4  
                                           
Income taxes
  30,116       22,974     31.1       55,808       45,565     22.5  
                                           
Net earnings
$ 81,425     $ 53,605     51.9   $ 149,843     $ 106,318     40.9 %  
                                           
Net earnings per share:
                                         
         Basic
$ 1.13     $ 0.76     48.7 %     $ 2.09     $ 1.50     39.3 %  
                                           
         Diluted
$ 1.09     $ 0.75     45.3 %     $ 2.04     $ 1.48     37.8 %  
                                           
Weighted average shares outstanding:
                                         
         Basic
  72,128       70,836             71,748       70,678        
                                           
         Diluted
  74,882       71,805             73,420       71,657        
                                           
 
 
 

 
 
KINETIC CONCEPTS, INC. AND SUBSIDIARIES
 
Condensed Consolidated Balance Sheets
 
(in thousands)
 
             
             
   
June 30,
   
December 31,
 
   
2011
   
2010
 
   
(unaudited)
       
             
Assets:
           
Current assets:
           
   Cash and cash equivalents
  $ 498,424     $ 316,603  
   Accounts receivable, net
    411,095       414,083  
   Inventories, net
    168,647       172,552  
   Deferred income taxes
    29,065       30,112  
   Prepaid expenses and other
    47,738       34,199  
                 
          Total current assets
    1,154,969       967,549  
                 
Net property, plant and equipment
    299,332       271,063  
Debt issuance costs, net
    30,691       22,622  
Deferred income taxes
    20,597       17,151  
Goodwill
    1,328,881       1,328,881  
Identifiable intangible assets, net
    443,922       453,802  
Other non-current assets
    15,537       14,931  
                 
    $ 3,293,929     $ 3,075,999  
                 
Liabilities and Shareholders' Equity:
               
Current liabilities:
               
   Accounts payable
  $ 51,227     $ 60,137  
   Accrued expenses and other
    241,628       225,524  
   Current installments of long-term debt
    27,500       169,500  
                 
          Total current liabilities
    320,355       455,161  
                 
Long-term debt, net of current installments and discount
    1,097,486       935,290  
Non-current tax liabilities
    37,395       35,588  
Deferred income taxes
    140,996       163,386  
Other non-current liabilities
    2,650       3,495  
                 
          Total liabilities
    1,598,882       1,592,920  
                 
Shareholders' equity:
               
   Common stock; authorized 225,000 at 2011 and 2010,
               
      issued and outstanding 72,928 at 2011 and 71,996 at 2010
    73       72  
   Preferred stock; authorized 50,000 at 2011 and 2010; issued and
               
      outstanding 0 at 2011 and 2010
    -       -  
   Additional paid-in capital
    904,845       852,152  
   Retained earnings
    763,277       613,434  
   Accumulated other comprehensive income, net
    26,852       17,421  
                 
          Shareholders' equity
    1,695,047       1,483,079  
                 
    $ 3,293,929     $ 3,075,999  
                 
 
 
 

 
 
 
KINETIC CONCEPTS, INC. AND SUBSIDIARIES
 
Condensed Consolidated Statements of Cash Flows
 
(in thousands)
 
(unaudited)
 
       
       
   
Six months ended June 30,
 
   
2011
   
2010
 
Cash flows from operating activities:
           
   Net earnings
  $ 149,843     $ 106,318  
   Adjustments to reconcile net earnings to net cash provided
               
      by operating activities:
               
           Amortization of convertible debt discount
    11,279       10,443  
           Depreciation and other amortization
    71,685       80,511  
           Provision for bad debt
    5,364       4,139  
           Write-off of deferred debt issuance costs
    3,218       1,928  
           Share-based compensation expense
    15,879       15,434  
           Deferred income tax benefit
    (21,061 )     (29,647 )
           Excess tax benefit from share-based payment arrangements
    (2,082 )     (1,392 )
           Change in assets and liabilities:
               
                 Decrease in accounts receivable, net
    3,586       30,932  
                 Decrease (increase) in inventories, net
    4,504       (36,102 )
                 Increase in prepaid expenses and other
    (13,540 )     (4,193 )
                 Decrease in accounts payable
    (8,585 )     (632 )
                 Increase (decrease) in accrued expenses and other
    17,824       (20,687 )
                 Increase (decrease) in tax liabilities, net
    2,088       (18,692 )
                 Decrease in deferred income taxes, net
    (3,541 )     (460 )
                 
                     Net cash provided by operating activities
    236,461       137,900  
                 
Cash flows from investing activities:
               
   Additions to property, plant and equipment
    (66,750 )     (46,192 )
   Decrease (increase) in inventory to be converted into equipment
               
      for short-term rental
    (7,239 )     7,265  
   Dispositions of property, plant and equipment
    913       1,067  
   Increase in identifiable intangible assets and other non-current assets
    (17,364 )     (2,091 )
                 
                     Net cash used by investing activities
    (90,440 )     (39,951 )
                 
Cash flows from financing activities:
               
   Repayments of long-term debt, revolving credit facility and
               
      capital lease obligations
    (13,830 )     (125,054 )
   Proceeds from exercise of stock options
    36,004       10,185  
   Proceeds from the purchase of stock in ESPP and other
    4,107       3,451  
   Excess tax benefit from share-based payment arrangements
    2,082       1,392  
   Purchase of immature shares for minimum tax withholdings
    (3,681 )     (1,108 )
   Refinancing of senior credit facility:
               
      Proceeds from borrowings on refinancing of senior credit facility
    146,012       -  
      Repayments on senior credit facility – due 2013
    (123,346 )     -  
      Payment of debt issuance costs
    (14,676 )     -  
                 
                     Net cash provided (used) by financing activities
    32,672       (111,134 )
                 
Effect of exchange rate changes on cash and cash equivalents
    3,128       (2,904 )
                 
Net increase (decrease) in cash and cash equivalents
    181,821       (16,089 )
Cash and cash equivalents, beginning of period
    316,603       263,157  
                 
Cash and cash equivalents, end of period
  $ 498,424     $ 247,068  
 
 
 

 

KINETIC CONCEPTS, INC. AND SUBSIDIARIES
 
Reconciliation from GAAP to Non-GAAP
 
Supplemental Revenue Data
 
(in thousands)
 
(unaudited)
 
                                 
                                 
 
Three months ended June 30,
           
 
2011
       
GAAP
   
Constant
 
             
Constant
   
2010
 
%
   
Currency %
 
 
GAAP
   
FX Impact
   
Currency
   
GAAP
 
Change
   
Change (1)
 
                                 
Total Revenue:
           
 
                 
  AHS
$ 357,971     $ (11,382 )   $ 346,589     $ 347,726   2.9 %   (0.3 ) %
  LifeCell
  96,330       (380 )     95,950       83,743   15.0     14.6  
  TSS
  65,529       (3,334 )     62,195       66,303   (1.2 )   (6.2 )
                                         
         Total Revenue
$ 519,830     $ (15,096 )   $ 504,734     $ 497,772   4.4 %   1.4 %
                                         
  AHS:
                                       
  Americas revenue
                                       
     Rental
$ 184,478     $ (325 )   $ 184,153     $ 189,076   (2.4 ) %   (2.6 ) %
     Sales
  82,381       (365 )     82,016       77,605   6.2     5.7  
                                         
         Total Americas revenue
  266,859       (690 )     266,169       266,681   0.1     (0.2 )
                                         
  EMEA revenue
                                       
     Rental
  31,775       (3,744 )     28,031       33,271   (4.5 )   (15.7 )
     Sales
  43,380       (5,040 )     38,340       38,648   12.2     (0.8 )
                                         
         Total EMEA revenue
  75,155       (8,784 )     66,371       71,919   4.5     (7.7 )
                                         
  APAC revenue
                                       
     Rental
  8,861       (995 )     7,866       4,502   96.8     74.7  
     Sales
  7,096       (913 )     6,183       4,624   53.5     33.7  
                                         
         Total APAC revenue
  15,957       (1,908 )     14,049       9,126   74.9     53.9  
                                         
     Total rental revenue
  225,114       (5,064 )     220,050       226,849   (0.8 )   (3.0 )
     Total sales revenue
  132,857       (6,318 )     126,539       120,877   9.9     4.7  
                                         
         Total AHS Revenue
$ 357,971     $ (11,382 )   $ 346,589     $ 347,726   2.9 %   (0.3 ) %
                                         
  LifeCell Revenue:
                                       
  Americas revenue
                                       
     Rental
$ 355     $ -     $ 355     $ -   - %   - %
     Sales
  92,913       (49 )     92,864       82,188   13.0     13.0  
                                         
         Total Americas revenue
  93,268       (49 )     93,219       82,188   13.5     13.4  
                                         
  EMEA revenue
                                       
     Sales
  3,062       (331 )     2,731       1,555   96.9     75.6  
                                         
     Total rental revenue
  355       -       355       -   -     -  
     Total sales revenue
  95,975       (380 )     95,595       83,743   14.6     14.2  
                                         
         Total LifeCell Revenue
$ 96,330     $ (380 )   $ 95,950     $ 83,743   15.0 %   14.6 %
                                         
  TSS Revenue:
                                       
  Americas revenue
                                       
     Rental
$ 33,505     $ (321 )   $ 33,184     $ 38,584   (13.2 ) %   (14.0 ) %
     Sales
  7,461       (109 )     7,352       5,979   24.8     23.0  
                                         
         Total Americas revenue
  40,966       (430 )     40,536       44,563   (8.1 )   (9.0 )
                                         
  EMEA revenue
                                       
     Rental
  20,323       (2,457 )     17,866       17,648   15.2     1.2  
     Sales
  3,868       (412 )     3,456       3,916   (1.2 )   (11.7 )
                                         
         Total EMEA revenue
  24,191       (2,869 )     21,322       21,564   12.2     (1.1 )
                                         
  APAC revenue
                                       
     Rental
  17       (1 )     16       3   466.7     433.3  
     Sales
  355       (34 )     321       173   105.2     85.5  
                                         
         Total APAC revenue
  372       (35 )     337       176   111.4     91.5  
                                         
     Total rental revenue
  53,845       (2,779 )     51,066       56,235   (4.3 )   (9.2 )
     Total sales revenue
  11,684       (555 )     11,129       10,068   16.1     10.5  
                                         
         Total TSS Revenue
$ 65,529     $ (3,334 )   $ 62,195     $ 66,303   (1.2 ) %   (6.2 ) %
                                         
                                   
 
(1) Represents percentage change between 2011 Non-GAAP Constant Currency revenue and 2010 GAAP revenue.
 
 
 
 

 
 
KINETIC CONCEPTS, INC. AND SUBSIDIARIES
 
Reconciliation from GAAP to Non-GAAP
 
Supplemental Revenue Data
 
(in thousands)
 
(unaudited)
 
                                 
                                 
 
Six months ended June 30,
           
 
2011
       
GAAP
   
Constant
 
             
Constant
   
2010
 
%
   
Currency %
 
 
GAAP
   
FX Impact
   
Currency
   
GAAP
 
Change
   
Change (1)
 
                                 
Total Revenue:
           
 
                 
  AHS
$ 698,510     $ (12,815 )   $ 685,695     $ 680,679   2.6 %   0.7 %
  LifeCell
  189,344       (587 )     188,757       162,758   16.3     16.0  
  TSS
  133,160       (3,509 )     129,651       140,140   (5.0 )   (7.5 )
                                         
         Total Revenue
$ 1,021,014     $ (16,911 )   $ 1,004,103     $ 983,577   3.8 %   2.1 %
                                         
  AHS:
                                       
  Americas revenue
                                       
     Rental
$ 366,340     $ (599 )   $ 365,741     $ 368,069   (0.5 ) %   (0.6 ) %
     Sales
  158,379       (637 )     157,742       148,444   6.7     6.3  
                                         
         Total Americas revenue
  524,719       (1,236 )     523,483       516,513   1.6     1.3  
                                         
  EMEA revenue
                                       
     Rental
  62,224       (3,444 )     58,780       68,856   (9.6 )   (14.6 )
     Sales
  81,871       (5,216 )     76,655       78,668   4.1     (2.6 )
                                         
         Total EMEA revenue
  144,095       (8,660 )     135,435       147,524   (2.3 )   (8.2 )
                                         
  APAC revenue
                                       
     Rental
  16,821       (1,562 )     15,259       8,281   103.1     84.3  
     Sales
  12,875       (1,357 )     11,518       8,361   54.0     37.8  
                                         
         Total APAC revenue
  29,696       (2,919 )     26,777       16,642   78.4     60.9  
                                         
     Total rental revenue
  445,385       (5,605 )     439,780       445,206   -     (1.2 )
     Total sales revenue
  253,125       (7,210 )     245,915       235,473   7.5     4.4  
                                         
         Total AHS Revenue
$ 698,510     $ (12,815 )   $ 685,695     $ 680,679   2.6 %   0.7 %
                                         
  LifeCell Revenue:
                                       
  Americas revenue
                                       
     Rental
$ 590     $ -     $ 590     $ -   - %   - %
     Sales
  182,915       (70 )     182,845       160,162   14.2     14.2  
                                         
         Total Americas revenue
  183,505       (70 )     183,435       160,162   14.6     14.5  
                                         
  EMEA revenue
                                       
     Sales
  5,839       (517 )     5,322       2,596   124.9     105.0  
                                         
     Total rental revenue
  590       -       590       -   -     -  
     Total sales revenue
  188,754       (587 )     188,167       162,758   16.0     15.6  
                                         
         Total LifeCell Revenue
$ 189,344     $ (587 )   $ 188,757     $ 162,758   16.3 %   16.0 %
                                         
  TSS Revenue:
                                       
  Americas revenue
                                       
     Rental
$ 72,028     $ (617 )   $ 71,411     $ 79,994   (10.0 ) %   (10.7 ) %
     Sales
  13,491       (215 )     13,276       12,969   4.0     2.4  
                                         
         Total Americas revenue
  85,519       (832 )     84,687       92,963   (8.0 )   (8.9 )
                                         
  EMEA revenue
                                       
     Rental
  39,990       (2,295 )     37,695       37,828   5.7     (0.4 )
     Sales
  7,071       (307 )     6,764       8,625   (18.0 )   (21.6 )
                                         
         Total EMEA revenue
  47,061       (2,602 )     44,459       46,453   1.3     (4.3 )
                                         
  APAC revenue
                                       
     Rental
  21       (6 )     15       47   (55.3 )   (68.1 )
     Sales
  559       (69 )     490       677   (17.4 )   (27.6 )
                                         
         Total APAC revenue
  580       (75 )     505       724   (19.9 )   (30.2 )
                                         
     Total rental revenue
  112,039       (2,918 )     109,121       117,869   (4.9 )   (7.4 )
     Total sales revenue
  21,121       (591 )     20,530       22,271   (5.2 )   (7.8 )
                                         
         Total TSS Revenue
$ 133,160     $ (3,509 )   $ 129,651     $ 140,140   (5.0 ) %   (7.5 ) %
                                         
                                   
 
(1) Represents percentage change between 2011 Non-GAAP Constant Currency revenue and 2010 GAAP revenue.
 
 
 
 

 
 
     KINETIC CONCEPTS, INC. AND SUBSIDIARIES  
     Selected Financial Information - GAAP to Non-GAAP Reconciliation  
     (in thousands, except per share data)  
     (unaudited)  
       
       
   
Three months ended June 30,
 
               
Interest
                     
               
Expense -
                     
           
Debt
 
Adoption of
 
Refinancing
                 
       
Amortization
 
Issuance
 
Required
 
of Senior
 
Restructuring
             
   
2011
 
of Acquired
 
Cost
 
Accounting
 
Credit
 
and Other
 
Adjusted
 
Adjusted
 
%
 
   
GAAP
 
Intangibles
 
Amortization
 
Standards
 
Facility
 
Charges
 
2011
 
2010
 
Change
 
                                       
Operating earnings
  $ 128,637   $ 8,856   $ -   $ -   $ -   $ 1,206   $ 138,699   $ 123,624   12.2
Net earnings (1)
  $ 81,425   $ 5,447   $ 1,065   $ 3,502   $ -   $ 742   $ 92,181   $ 72,533   27.1
Diluted earnings per share
  $ 1.09   $ 0.07   $ 0.01   $ 0.05   $ -   $ 0.01   $ 1.23   $ 1.01   21.8 %
 

   
Six months ended June 30,
 
               
Interest
                     
               
Expense -
                     
           
Debt
 
Adoption of
 
Refinancing
                 
       
Amortization
 
Issuance
 
Required
 
of Senior
 
Restructuring
             
   
2011
 
of Acquired
 
Cost
 
Accounting
 
Credit
 
and Other
 
Adjusted
 
Adjusted
 
%
 
   
GAAP
 
Intangibles
 
Amortization
 
Standards
 
Facility
 
Charges
 
2011
 
2010
 
Change
 
                                       
Operating earnings
  $ 243,204   $ 17,712   $ -   $ -   $ -   $ 1,206   $ 262,122   $ 235,123   11.5
Net earnings (1)
  $ 149,843   $ 10,893   $ 2,084   $ 6,937   $ 1,979   $ 742   $ 172,478   $ 137,125   25.8
Diluted earnings per share
  $ 2.04   $ 0.15   $ 0.03   $ 0.09   $ 0.03   $ 0.01   $ 2.35   $ 1.91   23.0

 
   
Three months ended June 30,
 
               
Interest
         
               
Expense -
         
           
Debt
 
Adoption of
         
       
Amortization
 
Issuance
 
Required
 
Restructuring
     
   
2010
 
of Acquired
 
Cost
 
Accounting
 
and Other
 
Adjusted
 
   
GAAP
 
Intangibles
 
Amortization
 
Standards
 
Charges
 
2010
 
                           
Operating earnings
  $ 101,357   $ 9,556   $ -   $ -   $ 12,711   $ 123,624  
Net earnings (1)
  $ 53,605   $ 5,878   $ 1,989   $ 3,243   $ 7,818   $ 72,533  
Diluted earnings per share
  $ 0.75   $ 0.08   $ 0.03   $ 0.04   $ 0.11   $ 1.01  

 
   
Six months ended June 30,
 
               
Interest
         
               
Expense -
         
           
Debt
 
Adoption of
         
       
Amortization
 
Issuance
 
Required
 
Restructuring
     
   
2010
 
of Acquired
 
Cost
 
Accounting
 
and Other
 
Adjusted
 
   
GAAP
 
Intangibles
 
Amortization
 
Standards
 
Charges
 
2010
 
                           
Operating earnings
  $ 202,697   $ 19,715   $ -   $ -   $ 12,711   $ 235,123  
Net earnings (1)
  $ 106,318   $ 12,125   $ 4,441   $ 6,423   $ 7,818   $ 137,125  
Diluted earnings per share
  $ 1.48   $ 0.17   $ 0.06   $ 0.09   $ 0.11   $ 1.91  
                                       
                                   
                                     
(1) Adjustments to “Net earnings” are presented net of tax.  The tax effect of each reconciling item is calculated using the Company’s estimated incremental U.S. combined federal and state tax rate of 38.5%.